Thursday, June 30, 2022


Category: Pharma

Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain

ETX-810 is an investigational first-in-class, oral, non-opioid, new chemical entity (NCE) prodrug of the bioactive lipid palmitoylethanolamide

SIGA Technologies Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

Procurement orders from new international jurisdictions have occurred as SIGA Technologies has received a large and ongoing number of inquiries about accessing oral TPOXX, highlighting the importance of health security preparedness.

Theramex Announces European Commission Marketing Authorization for Yselty ® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Symptoms of Uterine Fibroids

Linzagolix ® is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.

Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil

“This regulatory submission is an important milestone as we continue to expand our commitment to NMOSD patients around the world,” said Vikram Karnani, executive vice president and president, international operations, Horizon Therapeutics.

Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadian Society for Virology

“The virus-host Interface: A treasure trove of novel antiviral targets,” includes research sponsored by Tonix Pharmaceuticals focused on the development and testing of Wnt/β-Catenin signaling pathway inhibitors as broad-spectrum antivirals against SARS-CoV-2 and other emerging viruses.

Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene

The long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant Pharmaceuticals to expand Aptar’s production in support of OPNT003.